Progentec Diagnostics

Progentec Diagnostics, Inc. was established to explore and commercialize state-of-the-art diagnostic interventions in therapeutic areas with a high level of unmet medical need. The company is dedicated to improving health outcomes for individuals with autoimmune diseases through clinically validated biomarker testing and digital health solutions. Based in Oklahoma City at the Oklahoma Medical Research Foundation, Progentec operates a CLIA-certified and CAP-accredited laboratory, combining proprietary blood biomarkers with high sensitivity and specificity to provide comprehensive solutions for autoimmune disease management.

The company is developing biological and digital biomarkers primarily focused on systemic lupus erythematosus (SLE) and multiple sclerosis. Their flagship aiSLE® DX family of tests includes the Flare Risk Index, which can predict lupus flares up to 12 weeks in advance, and the Disease Activity Index, both powered by proprietary liquid biopsy technologies. Through their aiSLE MGMT platform, Progentec integrates these diagnostic tests with patient-generated data from their [AutoimmuneCorner] mobile application and wearable devices, providing clinicians with unprecedented insight into disease activity and patient experience. The company also maintains LupusCorner®, a patient engagement platform serving over 120,000 lupus warriors with tracking tools, health information, and community forums. Progentec collaborates with major institutions including Mayo Clinic Laboratories and various NIH-designated Autoimmunity Centers of Excellence to advance their mission of transforming autoimmune disease care.